Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Ana Espinel-Ingroff

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Procedures

Microbial Sensitivity Tests

Living Beings

Physiology

Fungal Drug Resistance

Disorders

Concepts & Ideas

Reproducibility of Results

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
32
Pfaller, Michael
14
WALSH, THOMAS
11
Rex, John
11
Rinaldi, Michael
10
Cantón, Emilia
10
Pemán, Javier
9
Ghannoum, Mahmoud
7
Galgiani, John
5
Gobernado, Miguel
4
Ghannoum, Mahmoud
4
McGinnis, Michael
4
Messer, Shawn
4
Sheehan, Daniel
3
Quindos, Guillermo
3
Viudes, Angel

Sign-in to see all Coauthors

Publications

TOP 3
Araujo Ricardo; Espinel-Ingroff Ana
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
Pfaller M A; Diekema D J; Ghannoum M A; Rex J H; Alexander B D; Andes D; Brown S D; Chaturvedi V; Espinel-Ingroff A; Fowler C L; Johnson E M; Knapp C C; Motyl M R; Ostrosky-Zeichner L; Sheehan D J; Walsh T J;
Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods.
Espinel-Ingroff Ana; Canton E; Peman J; Rinaldi M G; Fothergill A W
Comparison of 24-hour and 48-hour voriconazole MICs as determined by the Clinical and Laboratory Standards Institute broth microdilution method (M27-A3 document) in three laboratories: results obtained with 2,162 clinical isolates of Candida spp. and other yeasts.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Ana Espinel-Ingroff (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Araujo Ricardo; Espinel-Ingroff Ana
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.
Antimicrobial agents and chemotherapy 2009;53(11):4921-3.
2009: Pfaller M A; Diekema D J; Ghannoum M A; Rex J H; Alexander B D; Andes D; Brown S D; Chaturvedi V; Espinel-Ingroff A; Fowler C L; Johnson E M; Knapp C C; Motyl M R; Ostrosky-Zeichner L; Sheehan D J; Walsh T J;
Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods.
Journal of clinical microbiology 2009;47(10):3142-6.
2009: Espinel-Ingroff Ana; Canton E; Peman J; Rinaldi M G; Fothergill A W
Comparison of 24-hour and 48-hour voriconazole MICs as determined by the Clinical and Laboratory Standards Institute broth microdilution method (M27-A3 document) in three laboratories: results obtained with 2,162 clinical isolates of Candida spp. and other yeasts.
Journal of clinical microbiology 2009;47(9):2766-71.
2009: Cantón Emilia; Pemán Javier; Valentín Amparo; Espinel-Ingroff Ana; Gobernado Miguel
In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies.
Antimicrobial agents and chemotherapy 2009;53(7):3108-11.
2009: Pemán Javier; Cantón Emilia; Espinel-Ingroff Ana
Antifungal drug resistance mechanisms.
Expert review of anti-infective therapy 2009;7(4):453-60.
2009: Espinel-Ingroff Ana
Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009).
Revista iberoamericana de micología : órgano de la Asociación Española de Especialistas en Micología 2009;26(1):15-22.
2009: Cantón Emilia; Espinel-Ingroff Ana; Pemán Javier
Trends in antifungal susceptibility testing using CLSI reference and commercial methods.
Expert review of anti-infective therapy 2009;7(1):107-19.
2008: Araujo Ricardo; Coutinho Isabel; Espinel-Ingroff Ana
Rapid method for testing the susceptibility of Aspergillus fumigatus to amphotericin B, itraconazole, voriconazole and posaconazole by assessment of oxygen consumption.
The Journal of antimicrobial chemotherapy 2008;62(6):1277-80.
2008: Johnson Elizabeth; Espinel-Ingroff Ana; Szekely Adrien; Hockey Hans; Troke Peter
Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
International journal of antimicrobial agents 2008;32(6):511-4.
2008: Cantón Emilia; Pemán Javier; Valentín Amparo; Bosch Maria; Espinel-Ingroff Ana; Gobernado Miguel
Comparison of posaconazole and voriconazole in vitro killing against Candida krusei.
Diagnostic microbiology and infectious disease 2008;62(2):177-81.
2008: Espinel-Ingroff Ana
Mechanisms of resistance to antifungal agents: yeasts and filamentous fungi.
Revista iberoamericana de micología : órgano de la Asociación Española de Especialistas en Micología 2008;25(2):101-6.
2008: Espinel-Ingroff A; Canton E
Comparison of Neo-Sensitabs tablet diffusion assay with CLSI broth microdilution M38-A and disk diffusion methods for testing susceptibility of filamentous fungi with amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole.
Journal of clinical microbiology 2008;46(5):1793-803.
2008: Eraso Elena; Ruesga Maite; Villar-Vidal María; Carrillo-Muñoz Alfonso Javier; Espinel-Ingroff Ana; Quindós Guillermo
Comparative evaluation of ATB Fungus 2 and Sensititre YeastOne panels for testing in vitro Candida antifungal susceptibility.
Revista iberoamericana de micología : órgano de la Asociación Española de Especialistas en Micología 2008;25(1):3-6.
2008: Espinel-Ingroff Ana; Johnson Elizabeth; Hockey Hans; Troke Peter
Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies.
The Journal of antimicrobial chemotherapy 2008;61(3):616-20.
2008: Cantón Emilia; Pemán Javier; Espinel-Ingroff Ana; Martín-Mazuelos Estrella; Carrillo-Muñoz Alfonso; Martínez José Pedro
Comparison of disc diffusion assay with the CLSI reference method (M27-A2) for testing in vitro posaconazole activity against common and uncommon yeasts.
The Journal of antimicrobial chemotherapy 2008;61(1):135-8.
2007: Queiroz-Telles Flavio; Goldani Luciano Z; Schlamm Haran T; Goodrich James M; Espinel-Ingroff Ana; Shikanai-Yasuda Maria A
An open-label comparative pilot study of oral voriconazole and itraconazole for long-term treatment of paracoccidioidomycosis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2007;45(11):1462-9.
2007: Espinel-Ingroff A; Fothergill A; Ghannoum M; Manavathu E; Ostrosky-Zeichner L; Pfaller M A; Rinaldi M G; Schell W; Walsh T J
Quality control and reference guidelines for CLSI broth microdilution method (M38-A document) for susceptibility testing of anidulafungin against molds.
Journal of clinical microbiology 2007;45(7):2180-2.
2007: Espinel-Ingroff A; Arthington-Skaggs B; Iqbal N; Ellis D; Pfaller M A; Messer S; Rinaldi M; Fothergill A; Gibbs D L; Wang A
Multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B, and caspofungin.
Journal of clinical microbiology 2007;45(6):1811-20.
2007: Espinel-Ingroff A; Canton E; Gibbs D; Wang A
Correlation of Neo-Sensitabs tablet diffusion assay results on three different agar media with CLSI broth microdilution M27-A2 and disk diffusion M44-A results for testing susceptibilities of Candida spp. and Cryptococcus neoformans to amphotericin B, caspofungin, fluconazole, itraconazole, and voriconazole.
Journal of clinical microbiology 2007;45(3):858-64.
2007: Rodriguez-Tudela Juan Luis; Donnelly J Peter; Pfaller Michael A; Chryssantou Erja; Warn Peter; Denning David W; Espinel-Ingroff Ana; Barchiesi Francesco; Cuenca-Estrella Manuel
Statistical analyses of correlation between fluconazole MICs for Candida spp. assessed by standard methods set forth by the European Committee on Antimicrobial Susceptibility Testing (E.Dis. 7.1) and CLSI (M27-A2).
Journal of clinical microbiology 2007;45(1):109-11.
2006: Ghannoum M A; Arthington-Skaggs B; Chaturvedi V; Espinel-Ingroff A; Pfaller M A; Rennie R; Rinaldi M G; Walsh T J
Interlaboratory study of quality control isolates for a broth microdilution method (modified CLSI M38-A) for testing susceptibilities of dermatophytes to antifungals.
Journal of clinical microbiology 2006;44(12):4353-6.
2006: Espinel-Ingroff A
Comparison of three commercial assays and a modified disk diffusion assay with two broth microdilution reference assays for testing zygomycetes, Aspergillus spp., Candida spp., and Cryptococcus neoformans with posaconazole and amphotericin B.
Journal of clinical microbiology 2006;44(10):3616-22.
2006: Cantón E; Pemán J; Sastre M; Valentín A; Bosch M; Espinel-Ingroff A
[Evaluation and utility of the E-test and Neo-Sensitabs methods in studying fluconazole yeast susceptibility]
Revista española de quimioterapia : publicación oficial de la Sociedad Española de Quimioterapia 2006;19(3):267-74.
2006: Cantón Emilia; Pemán Javier; Sastre Macrina; Romero Mónica; Espinel-Ingroff Ana
Killing kinetics of caspofungin, micafungin, and amphotericin B against Candida guilliermondii.
Antimicrobial agents and chemotherapy 2006;50(8):2829-32.
2006: Pfaller M A; Diekema D J; Rex J H; Espinel-Ingroff A; Johnson E M; Andes D; Chaturvedi V; Ghannoum M A; Odds F C; Rinaldi M G; Sheehan D J; Troke P; Walsh T J; Warnock D W
Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints.
Journal of clinical microbiology 2006;44(3):819-26.
2005: Espinel-Ingroff A; Fothergill A; Ghannoum M; Manavathu E; Ostrosky-Zeichner L; Pfaller M; Rinaldi M; Schell W; Walsh T
Quality control and reference guidelines for CLSI broth microdilution susceptibility method (M 38-A document) for amphotericin B, itraconazole, posaconazole, and voriconazole.
Journal of clinical microbiology 2005;43(10):5243-6.
2005: Pina-Vaz Cidália; Costa-de-Oliveira Sofia; Rodrigues Acácio G; Espinel-Ingroff Ana
Comparison of two probes for testing susceptibilities of pathogenic yeasts to voriconazole, itraconazole, and caspofungin by flow cytometry.
Journal of clinical microbiology 2005;43(9):4674-9.
2005: Espinel-Ingroff A; Barchiesi F; Cuenca-Estrella M; Fothergill A; Pfaller M A; Rinaldi M; Rodriguez-Tudela J L; Verweij P E
Comparison of visual 24-hour and spectrophotometric 48-hour MICs to CLSI reference microdilution MICs of fluconazole, itraconazole, posaconazole, and voriconazole for Candida spp.: a collaborative study.
Journal of clinical microbiology 2005;43(9):4535-40.
2005: Cantón Emilia; Pemán Javier; Gobernado Miguel; Viudes Angel; Espinel-Ingroff Ana
Synergistic activities of fluconazole and voriconazole with terbinafine against four Candida species determined by checkerboard, time-kill, and Etest methods.
Antimicrobial agents and chemotherapy 2005;49(4):1593-6.
2004: Pfaller M A; Espinel-Ingroff A; Jones R N
Clinical evaluation of the Sensititre YeastOne colorimetric antifungal plate for antifungal susceptibility testing of the new triazoles voriconazole, posaconazole, and ravuconazole.
Journal of clinical microbiology 2004;42(10):4577-80.
2004: Castro Carmen; Serrano M Carmen; Flores Bernardo; Espinel-Ingroff Ana; Martín-Mazuelos Estrella
Comparison of the Sensititre YeastOne colorimetric antifungal panel with a modified NCCLS M38-A method to determine the activity of voriconazole against clinical isolates of Aspergillus spp.
Journal of clinical microbiology 2004;42(9):4358-60.
2004: Ghannoum M A; Chaturvedi V; Espinel-Ingroff A; Pfaller M A; Rinaldi M G; Lee-Yang W; Warnock D W
Intra- and interlaboratory study of a method for testing the antifungal susceptibilities of dermatophytes.
Journal of clinical microbiology 2004;42(7):2977-9.
2004: Cantón Emilia; Pemán Javier; Gobernado Miguel; Viudes Angel; Espinel-Ingroff Ana
Patterns of amphotericin B killing kinetics against seven Candida species.
Antimicrobial agents and chemotherapy 2004;48(7):2477-82.
2004: Serrano M C; Ramírez M; Morilla D; Valverde A; Chávez M; Espinel-Ingroff A; Claro R; Fernández A; Almeida C; Martín-Mazuelos E
A comparative study of the disc diffusion method with the broth microdilution and Etest methods for voriconazole susceptibility testing of Aspergillus spp.
The Journal of antimicrobial chemotherapy 2004;53(5):739-42.
2004: Espinel-Ingroff A; Montero D; Martin-Mazuelos E
Long-term preservation of fungal isolates in commercially prepared cryogenic microbank vials.
Journal of clinical microbiology 2004;42(3):1257-9.
2004: Espinel-Ingroff A; Pfaller M; Messer S A; Knapp C C; Holliday N; Killian S B
Multicenter comparison of the Sensititre YeastOne colorimetric antifungal panel with the NCCLS M27-A2 reference method for testing new antifungal agents against clinical isolates of Candida spp.
Journal of clinical microbiology 2004;42(2):718-21.
2003: Espinel-Ingroff Ana
In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.
Revista iberoamericana de micología : órgano de la Asociación Española de Especialistas en Micología 2003;20(4):121-36.
2003: Steinbach William J; Mitchell Thomas G; Schell Wiley A; Espinel-Ingroff Ana; Coico Richard F; Walsh Thomas J; Perfect John R
Status of medical mycology education.
Medical mycology : official publication of the International Society for Human and Animal Mycology 2003;41(6):457-67.
2003: Espinel-Ingroff Ana
Utility of mould susceptibility testing.
Current opinion in infectious diseases 2003;16(6):527-32.
2003: Serrano M C; Morilla D; Valverde A; Chávez M; Espinel-Ingroff A; Claro R; Ramírez M; Mazuelos E Martín
Comparison of Etest with modified broth microdilution method for testing susceptibility of Aspergillus spp. to voriconazole.
Journal of clinical microbiology 2003;41(11):5270-2.
2003: Durand-Joly Isabelle; Alfandari Serge; Benchikh Zinnédine; Rodrigue Marion; Espinel-Ingroff Ana; Catteau Benoit; Cordevant Christophe; Camus Daniel; Dei-Cas Eduardo; Bauters Francis; Delhaes Laurence; De Botton Stéphane
Successful outcome of disseminated Fusarium infection with skin localization treated with voriconazole and amphotericin B-lipid complex in a patient with acute leukemia.
Journal of clinical microbiology 2003;41(10):4898-900.
2003: Walsh Thomas J; Petraitis Vidmantas; Petraitiene Ruta; Field-Ridley Aida; Sutton Deanna; Ghannoum Mahmoud; Sein Tin; Schaufele Robert; Peter Joanne; Bacher John; Casler Heather; Armstrong Derek; Espinel-Ingroff Anna; Rinaldi Michael G; Lyman Caron A
Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B.
The Journal of infectious diseases 2003;188(2):305-19.
2003: Perfect John R; Marr Kieren A; Walsh Thomas J; Greenberg Richard N; DuPont Bertrand; de la Torre-Cisneros Juliàn; Just-Nübling Gudrun; Schlamm Haran T; Lutsar Irja; Espinel-Ingroff Ana; Johnson Elizabeth
Voriconazole treatment for less-common, emerging, or refractory fungal infections.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2003;36(9):1122-31.
2003: Cantón Emilia; Pemán Javier; Viudes Angel; Quindós Guillermo; Gobernado Miguel; Espinel-Ingroff Ana
Minimum fungicidal concentrations of amphotericin B for bloodstream Candida species.
Diagnostic microbiology and infectious disease 2003;45(3):203-6.
2003: Espinel-Ingroff Ana
Evaluation of broth microdilution testing parameters and agar diffusion Etest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991).
Journal of clinical microbiology 2003;41(1):403-9.
2003: Arévalo María Pilar; Carrillo-Muñoz Alfonso-Javier; Salgado Javier; Cardenes Delia; Brió Sonia; Quindós Guillermo; Espinel-Ingroff Ana
Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method.
The Journal of antimicrobial chemotherapy 2003;51(1):163-6.
2002: Espinel-Ingroff A; Chaturvedi V; Fothergill A; Rinaldi M G
Optimal testing conditions for determining MICs and minimum fungicidal concentrations of new and established antifungal agents for uncommon molds: NCCLS collaborative study.
Journal of clinical microbiology 2002;40(10):3776-81.
2002: Espinel-Ingroff A; Fothergill A; Peter J; Rinaldi M G; Walsh T J
Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS collaborative study.
Journal of clinical microbiology 2002;40(9):3204-8.
2002: Espinel-Ingroff Ana; Rezusta A
E-test method for testing susceptibilities of Aspergillus spp. to the new triazoles voriconazole and posaconazole and to established antifungal agents: comparison with NCCLS broth microdilution method.
Journal of clinical microbiology 2002;40(6):2101-7.
2001: Rex J H; Pfaller M A; Walsh T J; Chaturvedi V; Espinel-Ingroff A; Ghannoum M A; Gosey L L; Odds F C; Rinaldi M G; Sheehan D J; Warnock D W
Antifungal susceptibility testing: practical aspects and current challenges.
Clinical microbiology reviews 2001;14(4):643-58, table of contents.
2001: Espinel-Ingroff A; Bartlett M; Chaturvedi V; Ghannoum M; Hazen K C; Pfaller M A; Rinaldi M; Walsh T J
Optimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp.: NCCLS collaborative evaluation. National Committee for Clinical Laboratory Standards.
Antimicrobial agents and chemotherapy 2001;45(6):1828-35.
2001: Espinel-Ingroff A
Comparison of the E-test with the NCCLS M38-P method for antifungal susceptibility testing of common and emerging pathogenic filamentous fungi.
Journal of clinical microbiology 2001;39(4):1360-7.
2001: Espinel-Ingroff A
In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi.
Journal of clinical microbiology 2001;39(3):954-8.
2001: Espinel-Ingroff A
Germinated and nongerminated conidial suspensions for testing of susceptibilities of Aspergillus spp. to amphotericin B, itraconazole, posaconazole, ravuconazole, and voriconazole.
Antimicrobial agents and chemotherapy 2001;45(2):605-7.
2001: Espinel-Ingroff A; Boyle K; Sheehan D J
In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature.
Mycopathologia 2001;150(3):101-15.
2000: Barry A L; Pfaller M A; Brown S D; Espinel-Ingroff A; Ghannoum M A; Knapp C; Rennie R P; Rex J H; Rinaldi M G
Quality control limits for broth microdilution susceptibility tests of ten antifungal agents.
Journal of clinical microbiology 2000;38(9):3457-9.
2000: Espinel-Ingroff A
Clinical utility of in vitro antifungal susceptibility testing.
Revista española de quimioterapia : publicación oficial de la Sociedad Española de Quimioterapia 2000;13(2):161-6.
2000: Aller A I; Martin-Mazuelos E; Lozano F; Gomez-Mateos J; Steele-Moore L; Holloway W J; Gutiérrez M J; Recio F J; Espinel-Ingroff A
Correlation of fluconazole MICs with clinical outcome in cryptococcal infection.
Antimicrobial agents and chemotherapy 2000;44(6):1544-8.
2000: Espinel-Ingroff A; Warnock D W; Vazquez J A; Arthington-Skaggs B A
In vitro antifungal susceptibility methods and clinical implications of antifungal resistance.
Medical mycology : official publication of the International Society for Human and Animal Mycology 2000;38 Suppl 1():293-304.
1999: Espinel-Ingroff A; Vazquez J A; Boikov D; Pfaller M A
Evaluation of DNA-based typing procedures for strain categorization of Candida spp.
Diagnostic microbiology and infectious disease 1999;33(4):231-9.
1999: Espinel-Ingroff A; Pfaller M; Messer S A; Knapp C C; Killian S; Norris H A; Ghannoum M A
Multicenter comparison of the sensititre YeastOne Colorimetric Antifungal Panel with the National Committee for Clinical Laboratory standards M27-A reference method for testing clinical isolates of common and emerging Candida spp., Cryptococcus spp., and other yeasts and yeast-like organisms.
Journal of clinical microbiology 1999;37(3):591-5.
1999: Espinel-Ingroff A
Problems of antifungal in vitro testing in Aspergillus fumigatus.
Contributions to microbiology 1999;2():139-48.
1998: Espinel-Ingroff A
Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts.
Journal of clinical microbiology 1998;36(10):2950-6.
1998: Pfaller M A; Messer S A; Hollis R J; Espinel-Ingroff A; Ghannoum M A; Plavan H; Killian S B; Knapp C C
Multisite reproducibility of MIC results by the Sensititre YeastOne colorimetric antifungal susceptibility panel.
Diagnostic microbiology and infectious disease 1998;31(4):543-7.
1998: Espinel-Ingroff A; Stockman L; Roberts G; Pincus D; Pollack J; Marler J
Comparison of RapID yeast plus system with API 20C system for identification of common, new, and emerging yeast pathogens.
Journal of clinical microbiology 1998;36(4):883-6.
1998: Odds F C; Van Gerven F; Espinel-Ingroff A; Bartlett M S; Ghannoum M A; Lancaster M V; Pfaller M A; Rex J H; Rinaldi M G; Walsh T J
Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models.
Antimicrobial agents and chemotherapy 1998;42(2):282-8.
1998: Rex J H; Nelson P W; Paetznick V L; Lozano-Chiu M; Espinel-Ingroff A; Anaissie E J
Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis.
Antimicrobial agents and chemotherapy 1998;42(1):129-34.
1998: Espinel-Ingroff A
In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens.
Journal of clinical microbiology 1998;36(1):198-202.
1998: Espinel-Ingroff A; Barchiesi F; Hazen K C; Martinez-Suarez J V; Scalise G
Standardization of antifungal susceptibility testing and clinical relevance.
Medical mycology : official publication of the International Society for Human and Animal Mycology 1998;36 Suppl 1():68-78.
1997: Espinel-Ingroff A
Clinical relevance of antifungal resistance.
Infectious disease clinics of North America 1997;11(4):929-44.
1997: Rex J H; Pfaller M A; Galgiani J N; Bartlett M S; Espinel-Ingroff A; Ghannoum M A; Lancaster M; Odds F C; Rinaldi M G; Walsh T J; Barry A L
Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1997;24(2):235-47.
1997: Espinel-Ingroff A; Bartlett M; Bowden R; Chin N X; Cooper C; Fothergill A; McGinnis M R; Menezes P; Messer S A; Nelson P W; Odds F C; Pasarell L; Peter J; Pfaller M A; Rex J H; Rinaldi M G; Shankland G S; Walsh T J; Weitzman I
Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi.
Journal of clinical microbiology 1997;35(1):139-43.
1996: Anaissie E J; Paetznick V L; Ensign L G; Espinel-Ingroff A; Galgiani J N; Hitchcock C A; LaRocco M; Patterson T; Pfaller M A; Rex J H; Rinaldi M G
Microdilution antifungal susceptibility testing of Candida albicans and Cryptococcus neoformans with and without agitation: an eight-center collaborative study.
Antimicrobial agents and chemotherapy 1996;40(10):2387-91.
1996: Sanati H; Messer S A; Pfaller M; Witt M; Larsen R; Espinel-Ingroff A; Ghannoum M
Multicenter evaluation of broth microdilution method for susceptibility testing of Cryptococcus neoformans against fluconazole.
Journal of clinical microbiology 1996;34(5):1280-2.
1996: Espinel-Ingroff A
History of medical mycology in the united states.
Clinical microbiology reviews 1996;9(2):235-72.
1996: Espinel-Ingroff A; Pfaller M; Erwin M E; Jones R N
Interlaboratory evaluation of Etest method for testing antifungal susceptibilities of pathogenic yeasts to five antifungal agents by using Casitone agar and solidified RPMI 1640 medium with 2% glucose.
Journal of clinical microbiology 1996;34(4):848-52.
1996: Espinel-Ingroff A; Quart A; Steele-Moore L; Metcheva I; Buck G A; Bruzzese V L; Reich D
Molecular karyotyping of multiple yeast species isolated from nine patients with AIDS during prolonged fluconazole therapy.
Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology 1996;34(2):111-6.
1995: Espinel-Ingroff A; Rodríguez-Tudela J L; Martínez-Suárez J V
Comparison of two alternative microdilution procedures with the National Committee for Clinical Laboratory Standards reference macrodilution method M27-P for in vitro testing of fluconazole-resistant and -susceptible isolates of Candida albicans.
Journal of clinical microbiology 1995;33(12):3154-8.
1995: Pfaller M A; Bale M; Buschelman B; Lancaster M; Espinel-Ingroff A; Rex J H; Rinaldi M G; Cooper C R; McGinnis M R
Quality control guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of amphotericin B, fluconazole, and flucytosine.
Journal of clinical microbiology 1995;33(5):1104-7.
1995: Espinel-Ingroff A; Dawson K; Pfaller M; Anaissie E; Breslin B; Dixon D; Fothergill A; Paetznick V; Peter J; Rinaldi M
Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi.
Antimicrobial agents and chemotherapy 1995;39(2):314-9.
1994: Espinel-Ingroff A; Steele-Moore L
Comparison of fluconazole minimum inhibitory concentrations in three different formulations of RPMI-1640.
Diagnostic microbiology and infectious disease 1994;20(2):87-91.
1994: Espinel-Ingroff A; Steele-Moore L; Galgiani J N
Evaluation of 80% inhibition standards for the determination of fluconazole minimum inhibitory concentrations in three laboratories.
Diagnostic microbiology and infectious disease 1994;20(2):81-6.
1994: Espinel-Ingroff A
Etest for antifungal susceptibility testing of yeasts.
Diagnostic microbiology and infectious disease 1994;19(4):217-20.
1994: Pfaller M A; Bale M; Buschelman B; Lancaster M; Espinel-Ingroff A; Rex J H; Rinaldi M G
Selection of candidate quality control isolates and tentative quality control ranges for in vitro susceptibility testing of yeast isolates by National Committee for Clinical Laboratory Standards proposed standard methods.
Journal of clinical microbiology 1994;32(7):1650-3.
1994: Pfaller M A; Vu Q; Lancaster M; Espinel-Ingroff A; Fothergill A; Grant C; McGinnis M R; Pasarell L; Rinaldi M G; Steele-Moore L
Multisite reproducibility of colorimetric broth microdilution method for antifungal susceptibility testing of yeast isolates.
Journal of clinical microbiology 1994;32(7):1625-8.
1994: Pfaller M A; Buschelman B; Bale M J; Lancaster M; Espinel-Ingroff A; Rex J H; Rinaldi M G
Multicenter comparison of a colorimetric microdilution broth method with the reference macrodilution method for in vitro susceptibility testing of yeast isolates.
Diagnostic microbiology and infectious disease 1994;19(1):9-13.
1993: Lavoie S R; Espinel-Ingroff A; Kerkering T
Mixed cutaneous phaeohyphomycosis in a cocaine user.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1993;17(1):114-6.
1993: Fromtling R A; Galgiani J N; Pfaller M A; Espinel-Ingroff A; Bartizal K F; Bartlett M S; Body B A; Frey C; Hall G; Roberts G D
Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeasts.
Antimicrobial agents and chemotherapy 1993;37(1):39-45.
1992: Espinel-Ingroff A; Kish C W; Kerkering T M; Fromtling R A; Bartizal K; Galgiani J N; Villareal K; Pfaller M A; Gerarden T; Rinaldi M G
Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests.
Journal of clinical microbiology 1992;30(12):3138-45.
1992: Pfaller M A; Dupont B; Kobayashi G S; Müller J; Rinaldi M G; Espinel-Ingroff A; Shadomy S; Troke P F; Walsh T J; Warnock D W
Standardized susceptibility testing of fluconazole: an international collaborative study.
Antimicrobial agents and chemotherapy 1992;36(9):1805-9.
1991: Fincher R M; Fisher J F; Lovell R D; Newman C L; Espinel-Ingroff A; Shadomy H J
Infection due to the fungus Acremonium (cephalosporium).
Medicine 1991;70(6):398-409.
1991: Espinel-Ingroff A; Kerkering T M; Goldson P R; Shadomy S
Comparison study of broth macrodilution and microdilution antifungal susceptibility tests.
Journal of clinical microbiology 1991;29(6):1089-94.
1991: Espinel-Ingroff A; Kerkering T M
Spectrophotometric method of inoculum preparation for the in vitro susceptibility testing of filamentous fungi.
Journal of clinical microbiology 1991;29(2):393-4.
1991: Espinel-Ingroff A; Shadomy S; White S
Agar disk diffusion susceptibility tests with cilofungin (LY 121019).
Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology 1991;29(2):93-8.
1990: Pfaller M A; Rinaldi M G; Galgiani J N; Bartlett M S; Body B A; Espinel-Ingroff A; Fromtling R A; Hall G S; Hughes C E; Odds F C
Collaborative investigation of variables in susceptibility testing of yeasts.
Antimicrobial agents and chemotherapy 1990;34(9):1648-54.
1989: Espinel-Ingroff A; McGinnis M R; Pincus D H; Goldson P R; Kerkering T M
Evaluation of the API 20C yeast identification system for the differentiation of some dematiaceous fungi.
Journal of clinical microbiology 1989;27(11):2565-9.
1989: Espinel-Ingroff A; Shadomy S
In vitro and in vivo evaluation of antifungal agents.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1989;8(4):352-61.
1988: Espinel-Ingroff A; Goldson P R; McGinnis M R; Kerkering T M
Evaluation of proteolytic activity to differentiate some dematiaceous fungi.
Journal of clinical microbiology 1988;26(2):301-7.
1987: Galgiani J N; Reiser J; Brass C; Espinel-Ingroff A; Gordon M A; Kerkering T M
Comparison of relative susceptibilities of Candida species to three antifungal agents as determined by unstandardized methods.
Antimicrobial agents and chemotherapy 1987;31(9):1343-7.
1987: Stamm A M; Diasio R B; Dismukes W E; Shadomy S; Cloud G A; Bowles C A; Karam G H; Espinel-Ingroff A
Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis.
The American journal of medicine 1987;83(2):236-42.
1986: Shadomy S; Espinel-Ingroff A; Tartaglione T A; Dismukes W E
Treatment of systemic mycoses with ketoconazole: studies of ketoconazole serum levels.
Mykosen 1986;29(5):195-209.
1986: Espinel-Ingroff A; Shadomy S; Dixon D; Goldson P
Exoantigen test for Cladosporium bantianum, Fonsecaea pedrosoi, and Phialophora verrucosa.
Journal of clinical microbiology 1986;23(2):305-10.
1986: Tartaglione T A; Raffalovich A C; Poynor W J; Espinel-Ingroff A; Kerkering T M
Pharmacokinetics and tolerance of ciprofloxacin after sequential increasing oral doses.
Antimicrobial agents and chemotherapy 1986;29(1):62-6.
1985: Shadomy S; Espinel-Ingroff A; Gebhart R J
In-vitro studies with SF 86-327, a new orally active allylamine derivative.
Sabouraudia 1985;23(2):125-32.
1984: Espinel-Ingroff A; Shadomy S; Kerkering T M; Shadomy H J
Exoantigen test for differentiation of Exophiala jeanselmei and Wangiella dermatitidis isolates from other dematiaceous fungi.
Journal of clinical microbiology 1984;20(1):23-7.
1984: Espinel-Ingroff A; Shadomy S; Gebhart R J
In vitro studies with R 51,211 (itraconazole).
Antimicrobial agents and chemotherapy 1984;26(1):5-9.
1984: Shadomy S; Espinel-Ingroff A; Kerkering T M
In-vitro studies with four new antifungal agents: BAY n 7133, bifonazole (BAY h 4502), ICI 153,066 and Ro 14-4767/002.
Sabouraudia 1984;22(1):7-15.
1984: Gebhart R J; Espinel-Ingroff A; Shadomy S
In vitro susceptibility studies with oxiconazole (Ro 13-8996).
Chemotherapy 1984;30(4):244-7.
1983: Stafford C R; Fisher J F; Fadel H E; Espinel-Ingroff A V; Shadomy S; Hamby M
Cryptococcal meningitis in pregnancy.
Obstetrics and gynecology 1983;62(3 Suppl):35s-37s.
1983: Kerkering T M; Schwartz P M; Espinel-Ingroff A; Turek P J; Diasio R B
5-fluorocytosine susceptibility of pathogenic fungi in the presence of allopurinol: potential for improving the therapeutic index of 5-fluorocytosine.
Antimicrobial agents and chemotherapy 1983;24(3):448-9.
1982: Espinel-Ingroff A; Kerkering T M; Shadomy H J
Isolation of dematiaceous pathogenic fungi from a feed and seed warehouse.
Journal of clinical microbiology 1982;15(4):714-9.

Sign-in to see more